Hologic (Nasdaq: HOLX) announced today that it launched its Novodiag fully automated molecular diagnostic system in Europe. Marlborough, Massachusetts-based Hologic designed its Novodiag system for the on-demand testing of infectious diseases and antimicrobial resistance. The launch follows the company’s $795 million acquisition of Mobidiag this past summer. According to a news release, the Novodiag system […]
Mobidiag
Hologic completes $795M Mobidiag acquisition
Hologic (NSDQ:HOLX) today announced that it has completed its $795 million acquisition of diagnostic developer Mobidiag Oy. France-based Mobidiag develops PCR-based tests for acute care conditions, including gastrointestinal and respiratory infections, antimicrobial resistance management and healthcare-associated infections. Its Amplidiag and Novodiag platforms can deliver results in 50 minutes to two hours. Marlborough, Mass.-based Hologic announced the […]
Hologic earnings miss Wall Street expectations for Q2
Hologic (NSDQ:HOLX) posted second-quarter results today that trailed the consensus forecast, but the company forecasts a strong third quarter fueled by robust COVID-19 test revenue. The Marlborough, Mass.-based company posted profits of $1.09 billion, or $2.38 per share, on sales of $1.54 billion for the three months ended March 27, 2020. Sales growth in the […]
Hologic to acquire Mobidiag in $795M deal
Hologic (NSDQ:HOLX) announced today that it entered into a definitive agreement to acquire diagnostic developer Mobidiag Oy for $795 million. Finland/France–based Mobidiag develops and markets PCR-based tests for acute care conditions, including gastrointestinal and respiratory infections, antimicrobial resistance management and healthcare-associated infections. Mobidiag’s Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times […]